What is HC Wainwright’s Estimate for EBS Q3 Earnings?

Emergent Biosolutions Inc. (NYSE:EBS) – HC Wainwright issued their Q3 2026 earnings estimates for shares of Emergent Biosolutions in a note issued to investors on Monday, August 10th. HC Wainwright analyst R. Selvaraju anticipates that the biopharmaceutical company will post earnings per share of ($0.75) for the quarter. HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. HC Wainwright also issued estimates for Emergent Biosolutions’ Q4 2026 earnings at ($0.64) EPS, FY2026 earnings at ($4.63) EPS, Q1 2027 earnings at ($0.53) EPS, Q2 2027 earnings at $0.23 EPS, Q3 2027 earnings at $0.22 EPS, Q4 2027 earnings at $0.35 EPS and FY2027 earnings at $0.28 EPS.

Emergent Biosolutions (NYSE:EBS) last issued its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.68. The company had revenue of $234.30 million during the quarter, compared to the consensus estimate of $177.50 million. Emergent Biosolutions had a negative net margin of 22.95% and a positive return on equity of 16.35%.

EBS has been the topic of a number of other reports. Benchmark restated a “buy” rating on shares of Emergent Biosolutions in a report on Tuesday, June 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Emergent Biosolutions in a research report on Friday. Finally, UBS Group restated a “buy” rating on shares of Emergent Biosolutions in a research note on Tuesday, June 2nd. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $10.00.

Emergent Biosolutions Price Performance

EBS stock opened at $4.43 on Wednesday. The stock has a 50-day moving average price of $7.66 and a two-hundred day moving average price of $8.65. Emergent Biosolutions has a 1 year low of $4.36 and a 1 year high of $14.06. The stock has a market cap of $227.38 million, a PE ratio of -1.25 and a beta of 2.35. The company has a current ratio of 5.42, a quick ratio of 2.95 and a debt-to-equity ratio of 1.70.

Insider Transactions at Emergent Biosolutions

In other Emergent Biosolutions news, SVP Paul Anthony Williams sold 3,000 shares of the business’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $8.40, for a total transaction of $25,200.00. Following the sale, the senior vice president directly owned 159,098 shares of the company’s stock, valued at $1,336,423.20. The trade was a 1.85% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.00% of the company’s stock.

Hedge Funds Weigh In On Emergent Biosolutions

Several hedge funds have recently modified their holdings of the stock. CWM LLC increased its position in shares of Emergent Biosolutions by 5.5% in the fourth quarter. CWM LLC now owns 18,009 shares of the biopharmaceutical company’s stock worth $223,000 after purchasing an additional 942 shares during the period. Wealth Enhancement Advisory Services LLC lifted its position in Emergent Biosolutions by 14.3% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 13,016 shares of the biopharmaceutical company’s stock worth $171,000 after purchasing an additional 1,625 shares during the period. Franklin Resources Inc. grew its stake in Emergent Biosolutions by 2.3% during the fourth quarter. Franklin Resources Inc. now owns 78,945 shares of the biopharmaceutical company’s stock worth $976,000 after buying an additional 1,764 shares in the last quarter. SG Americas Securities LLC increased its holdings in Emergent Biosolutions by 4.6% in the 1st quarter. SG Americas Securities LLC now owns 42,394 shares of the biopharmaceutical company’s stock valued at $352,000 after buying an additional 1,865 shares during the period. Finally, Deutsche Bank AG increased its holdings in Emergent Biosolutions by 1.1% in the 4th quarter. Deutsche Bank AG now owns 181,744 shares of the biopharmaceutical company’s stock valued at $2,246,000 after buying an additional 1,941 shares during the period. Institutional investors own 78.40% of the company’s stock.

Key Stories Impacting Emergent Biosolutions

Here are the key news stories impacting Emergent Biosolutions this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and projects a recovery to positive earnings in 2027, including $0.28 in full-year EPS and positive EPS in the second through fourth quarters. However, its price target was reduced to $10 from $12, still implying substantial upside from recent levels. HC Wainwright lowers Emergent BioSolutions price target
• Neutral Sentiment: HC Wainwright expects EBS to remain unprofitable in the near term, forecasting EPS of ($0.75) for Q3 2026, ($0.64) for Q4 2026 and ($4.63) for full-year 2026. The firm then forecasts a ($0.53) loss in Q1 2027, followed by improving profitability in later quarters. HC Wainwright forecast for Emergent BioSolutions
• Negative Sentiment: Emergent BioSolutions cut its 2026 revenue guidance to $645 million-$675 million, down from the previously reaffirmed $720 million-$760 million outlook. The sharp reduction raises concerns about demand, execution and near-term cash flow. Emergent BioSolutions guidance cut and investigation notice
• Negative Sentiment: Levi & Korsinsky announced an investigation into potential securities-law violations related to Emergent’s business disclosures. The legal uncertainty adds another risk for shareholders following the guidance reduction. Levi and Korsinsky investigation notice

Emergent Biosolutions Company Profile

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.